#1 Clinical Trials Search in Europe

Other Blood Products

This article discusses a clinical trial investigating the use of andexanet alfa, a drug classified as “Other Blood Products,” in patients taking factor Xa inhibitors who require urgent surgery. The study aims to assess the safety and efficacy of andexanet alfa in reducing bleeding risk compared to usual care methods. This information is crucial for patients on anticoagulants who may need emergency procedures.

Table of Contents

What Are Other Blood Products?

Other blood products refer to a category of medical treatments derived from human blood that are used to manage various health conditions[1]. These products are different from whole blood transfusions and include specialized components that serve specific medical purposes. They are part of a broader group known as blood and related products, which play crucial roles in medical treatments and emergency situations.

Medical Conditions Treated

Other blood products are used to treat a variety of medical conditions, particularly those involving bleeding or clotting disorders. Some of the conditions that may be managed with these products include:

  • Reversal of anticoagulation effects: This is particularly important for patients taking blood thinners (anticoagulants) who need urgent surgery[1].
  • Bleeding disorders: Various inherited or acquired conditions that affect the body’s ability to form blood clots.
  • Surgical procedures: To manage or prevent excessive bleeding during or after surgery.
  • Trauma: In cases of severe injury where blood loss is a concern.

Usage in Clinical Trials

Other blood products are being studied in clinical trials to assess their effectiveness in various medical scenarios. For example, a current trial is investigating the use of these products in patients who are taking factor Xa inhibitors (a type of blood thinner) and require urgent surgery[1].

The trial aims to determine if certain blood products can effectively reverse the anticoagulation effect of these medications, thereby reducing the risk of bleeding during surgical procedures[1]. This research is crucial for improving patient care in emergency situations where rapid reversal of blood thinning effects is necessary.

Potential Benefits

The use of other blood products may offer several potential benefits:

  • Rapid reversal of anticoagulation: This can be life-saving in emergency situations requiring immediate surgery[1].
  • Reduced bleeding risk: By helping to restore normal blood clotting function.
  • Improved surgical outcomes: By allowing necessary procedures to be performed with lower risk of complications.
  • Targeted treatment: Unlike whole blood transfusions, specific blood products can address particular medical needs more precisely.

Administration

Other blood products are typically administered intravenously (through a vein) in a hospital or clinical setting. The specific product used, dosage, and duration of treatment will depend on the individual patient’s condition, the reason for treatment, and other medical factors[1].

In some cases, these products may be given as a bolus (a single, large dose) followed by a continuous infusion to maintain their effect over time[1]. The administration is usually overseen by healthcare professionals experienced in managing blood products and potential reactions.

Considerations and Precautions

While other blood products can be life-saving, there are important considerations to keep in mind:

  • Individual assessment: The use of these products should be based on a careful evaluation of each patient’s specific needs and medical history[1].
  • Potential reactions: As with any blood-derived product, there is a risk of allergic or other adverse reactions. Patients should be monitored closely during and after administration.
  • Balancing risks: The benefits of using these products must be weighed against potential risks, especially in emergency situations[1].
  • Ongoing research: As clinical trials continue, our understanding of the best uses and protocols for other blood products may evolve.

It’s important for patients to discuss any concerns or questions about other blood products with their healthcare provider. They can provide more detailed information based on individual medical circumstances and the latest research findings.

Aspect Details
Study Title A Randomized Study of Andexanet Alfa Compared to Usual Care in Patients Receiving a Factor Xa Inhibitor who Require Urgent Surgery or Procedure (ANNEXA-RS)
Main Objective To assess the ability of andexanet to achieve effective intraoperative hemostasis compared to usual care
Inclusion Criteria Patients on factor Xa inhibitors needing urgent surgery within 12 hours, high bleeding risk
Exclusion Criteria Acute life-threatening bleeding, dementia, certain bleeding disorders, prior andexanet use
Treatment Groups Andexanet alfa group (IV bolus + infusion) vs. Usual care group
Follow-up Period 4 visits over approximately 30 days, with possible additional test at 120 days
Primary Endpoint Effective intraoperative hemostasis
Secondary Endpoints Change in anti-FXa activity at start of surgery and 2 hours post-surgery

FAQ

  • What is the purpose of this clinical trial? The main purpose is to assess if andexanet alfa can effectively achieve intraoperative hemostasis (control of bleeding during surgery) compared to usual care in patients taking factor Xa inhibitors who need urgent surgery.
  • Who can participate in this trial? Participants must be taking a factor Xa inhibitor (like apixaban, rivaroxaban, or edoxaban), require urgent surgery within 12 hours, and have a high risk of bleeding. They must not have certain conditions like acute life-threatening bleeding or dementia.
  • How is the study conducted? Patients are randomly assigned to either receive andexanet alfa as an IV bolus followed by an infusion, or usual care based on the doctor's discretion and local guidelines. The study then follows up with patients for about 30 days after surgery.
  • What are the main outcomes being measured? The primary outcome is effective control of bleeding during surgery. Secondary outcomes include how quickly and sustainably andexanet alfa reverses the anticoagulation effect of factor Xa inhibitors compared to usual care.
  • How long does the study last for each participant? The study involves the surgery or procedure period, followed by 4 follow-up visits over approximately 30 days. Some patients may have an additional antibody test at 120 days post-surgery.

Ongoing Clinical Trials on Other Blood Products

  • Study on Andexanet Alfa for Patients on Factor Xa Inhibitors (Apixaban, Rivaroxaban, Edoxaban) Needing Urgent Surgery to Reduce Bleeding Risk

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark Estonia +13

Glossary

  • Andexanet alfa: A medication designed to reverse the anticoagulation effects of factor Xa inhibitors.
  • Factor Xa inhibitors: A class of anticoagulant medications that includes apixaban, rivaroxaban, and edoxaban, used to prevent blood clots.
  • Hemostasis: The process of stopping bleeding or hemorrhage in the body.
  • Intraoperative: Occurring or performed during a surgical operation.
  • Anti-FXa activity: A measure of the anticoagulant effect of factor Xa inhibitors in the blood.
  • IV bolus: A single, large dose of medication given intravenously (through a vein) over a short period.
  • Anticoagulation: The process of hindering blood clot formation using medications.
  • Thrombocytopenia: A condition characterized by abnormally low levels of platelets in the blood.
  • Coagulopathy: A condition affecting the blood's ability to form clots.
  • Hypersensitivity: An exaggerated or inappropriate immune response to a substance.

References

  1. http://clinicaltrials.eu/trial/study-on-andexanet-alfa-for-patients-on-factor-xa-inhibitors-apixaban-rivaroxaban-edoxaban-needing-urgent-surgery-to-reduce-bleeding-risk/